A Ab bs st tr ra ac ct t Prion diseases share common features of neurodegenerative disorders, infectious diseases and pathologies linked to misfolded proteins. Whether these aspects are independently and fortuitously present in prion diseases or are somewhat linked together remains unsettled, but the contribution of genomic, proteomic, metabolomic and spectroscopic techniques might give insights into this puzzle, and likely give hope for therapy to patients. Although the prion protein gene (PRNP) governs most of the clinical and pathological features of prion diseases and plays a pivotal role in determining host susceptibility, there are still many uncertainties and unknown risk factors that need to be clarified and identified. Several genes, other than PRNP, have recently been found to be associated with a risk of developing sporadic or variant Creutzfeldt-Jakob disease, but these novel data have been produced in a relatively small number of patients and controls and, therefore, need further confirmation. The same criticism applies to the identification of the over 20 new cerebrospinal fluid or plasma markers of disease. Some of these markers seem related to the massive brain damage that occurs, rather than being specific to prion infection. Nevertheless, genomic and post-genomic approaches have shown that these techniques are very powerful, and the best way to overcome the scantiness of samples would be to encourage strong collaboration between different centers of excellence in prion diseases. In this review, we describe the most recent and outstanding advances offered by genomics and postgenomics analyses in the field of human prion diseases. I In nt tr ro od du uc ct ti io on n Transmissible spongiform encephalopathies (TSEs), or prion diseases, are a group of fatal neurological disorders that affect humans and animals, and for which there is no available therapy [1] . The basic pathogenic mechanism is linked to post-translational changes of the host cellular prion protein (PrP c ) into a pathological conformer (PrP TSE ) that has a strong tendency to aggregate and form amyloid fibrils [2] . As for the Aβ amyloid present in Alzheimer's disease (AD), it is still unclear whether large aggregates of PrP TSE are more or less toxic to neural cells than small oligomers [3] . In humans, the most common form of disease is sporadic Creutzfeldt-Jakob disease (CJD), which equally affects both females and males of all ages, and of all ethnic groups [4] . Sporadic CJD has an overall mortality rate of approximately 1-2 cases per million people per year, with peak incidence in individuals aged between 60 and 70 years [4] . Approximately 10 to 20% of CJD cases appear within families [4, 5] and these forms are always (apart from very few exceptions, for example [6, 7] ) linked to point or insert mutations in the prion protein gene, PRNP, suggesting that these disorders are strongly linked to PRNP and that, unlike other neurodegenerative disorders such as AD, prion diseases are likely monogenetic. Other rare genetic forms of TSEs are fatal familial insomnia (FFI) and GerstmannSträussler-Scheinker syndrome (GSS). Both sporadic and genetic prion disorders are transmissible to a wide range of laboratory animals (rodents, felines, and non-human primates) by the injection of crude brain homogenates. Depending upon the host, the type of inoculum, and the route of inoculation, the lag period between the time of injection and the development of clinical signs may last for weeks, months or years [8] [9] [10] . Around one-third into this asymptomatic period, the host starts producing PrP TSE using its own PrP c as a substrate. At the end of the incubation period the host develops clinical, behavioral, and neurological signs, and finally dies, usually after a few weeks of disease. However, after prion infection, mice with ablated prion protein gene (knock-out mice) do not produce PrP TSE or clinical signs of disease, confirming the pivotal role of PrP c in the pathogenesis of prion disorders [11] . In experimental prion models, treatment with a variety of compounds during the asymptomatic phase of disease delays the formation of PrP TSE and the appearance of clinical signs [12] . In some cases, animals do not even develop disease [12] . However, there is virtually no beneficial effect if the treatment is started after the appearance of clinical signs, suggesting that the only possible approach in humans is prevention rather than therapy [13] . Naturally, prion diseases occur also in sheep and goats (scrapie disease), in cattle (bovine spongiform encephalopathy (BSE), and some very rare variants), and in cervids (chronic wasting disease (CWD)) [2] . A BSE epidemic, sustained by feeding cows with infected rendered meat, has produced a serious worldwide economic and health problem. Thousands of cattle have been killed in Europe and elsewhere to further prevent the rise of the epidemic and the possibility that BSE would transmit to humans. Despite these efforts, however, transmission of BSE to humans occurred in the 1990s and approximately 200 people, mostly in their 20s, died of a novel prion disease (variant CJD) [14] . Patients with variant CJD were probably infected via contaminated food in the late 1980s or early 1990s, but it is still unknown how many individuals are currently silently incubating the disease [15] . Occasionally, transmission of prion diseases occurs from man to man via improperly decontaminated surgical instruments, use of biological products taken from cadaveric human tissues [16], blood transfusion, or possibly plasmaderived products (so far these two modes of transmission have occurred only for variant CJD) [17, 18] .
G Ge en ne et ti ic c a an na al ly ys se es s i in n h hu um ma an n p pr ri io on n d di is se ea as se es s
In humans, the PRNP gene is the only strong factor that determines both susceptibility and phenotypes of prion diseases. This gene presents several point or insert mutations that are responsible for the appearance of familial forms of prion diseases, and often each specific mutation is associated with a specific clinico-pathological phenotype [19] . The most striking example is the mutation at codon 178 (substitution of the aspartic acid with asparagine), which gives rise to two different prion diseases depending on whether the mutation co-segregates with methionine (FFI) or valine (genetic CJD) in the polymorphic codon 129. On the other hand, there is also evidence that within the same family, mutated carriers either develop different clinical phenotypes [20, 21] , develop disease at different ages, or do not develop disease at all [5] . These findings suggest that some other factors are involved in determining susceptibility to the disease [22], but no specific genomic studies have so far been conducted to exploit the possible involvement of other genes. The only exception is the finding that in a large kindred of GSS-affected patients with the proline to leucine mutation at codon 102 of the PRNP gene, apolipoprotein E4 (ApoE4) carriers have a delay in the age of onset of approximately 10 years without, however, any influence on the clinico-phenotype of the disease [21] . Whether ApoE4 influences age at onset in other forms of genetic prion diseases remains to be determined.
The methionine/valine polymorphic site of the PRNP gene also influences susceptibility to sporadic, iatrogenic and variant CJD. Approximately 60% of sporadic and 100% of variant CJD patients are methionine homozygous, compared to 40% of Caucasian populations, suggesting that there is a genetic predisposition even in the non-hereditary forms of prion diseases [4] . Sporadic CJD is not a single entity and different subtypes show clinical and neuropathological features [19] ; some of them, such as disease survival, are partially determined by the polymorphic codon 129 but other factors might be involved in determining the rate of susceptibility, the age of onset, the clinical manifestations and, finally, disease duration [23] . Epidemiological and case-control studies have failed to identify convincing risk factors [24, 25] and though it is still theoretically possible that as-yet unidentified environmental events may contribute to the development of the disease, it is likely that other genes are involved in its pathogenesis.
G Ge en no om mi ic c f fi in nd di in ng gs s i in n h hu um ma an n p pr ri io on n d di is se ea as se es s . It is therefore conceivable that a potential deregulation of RARB and STMN2 might be involved in the pathogenesis of prion diseases, and hence lead to an increased susceptibility of variant or iatrogenic CJD from exogenous exposure. However, the authors [29] could not link the presence of SNPs in the upstream regions of RARB and STMN2 to a modification of their expression and, since these genes are not expressed in blood cells, their products cannot be used as possible markers for prion diseases. In two other studies, the same group [35, 36] reported two other genes (SPRN and HECTD2) found to be associated with risk of sporadic and variant CJD. SPRN was identified by comparative gene analysis [37] ; it encodes Shadoo (Sho, shadow of prion protein), a highly conserved protein that has possible functional links with the prion protein [38] , and different genetic variants have been associated with risk for either variant or sporadic CJD [35] . HECTD2 encodes an E3 ubiquitin ligase involved in regulating the incubation time of scrapie-infected mice [36] , and a single SNP, located in the intron of the gene, was significantly over-represented in both variant and sporadic CJD [36]. Moreover, a high level of HECTD2 mRNA expression seems to be linked with variant CJD in the UK population [36] . These studies are of great interest but it is somewhat surprising that upregulation of these genes was not found by the same group in their genome-wide association study for the identification of CJD risk-associated factors [29] .
In another study, Xiang and colleagues [39] applied global gene expression microarray technology to the frontal cortex of 15 patients with sporadic CJD and compared the global gene expression with frontal cortical samples of patients dying of unrelated diseases without clinical signs of neurological diseases, and with unremarkable neuropathology. They found several upregulated (n = 79) and downregulated (n = 275) genes in sporadic CJD compared to controls. Some of the upregulated genes are clearly linked to the pathological process of degeneration (for example, those encoding GFAP and S100; the latter protein is also increased in cerebrospinal fluid (CSF) and plasma of CJD patients), or to the immune and inflammatory responses that clearly occur in prion diseases [40] . The upregulation of genes encoding cysteine-rich intracellular proteins with a high capacity to bind to zinc and copper (that is, metallothionein-1 and -2) has also been previously reported in human prion diseases [41] . Reduced expression was observed in genes (SNAP-25 and synaptophysin) that are involved in synaptic function and plasticity and that were previously found at decreased levels in the cerebral cortex of CJD patients [42] . This work is of great interest in terms of identifying genes that are involved in the pathological process of prion diseases, but it is necessary to validate these results by using control patients with other neurodegenerative disorders, in order to identify prion-specific genes rather than hundreds of genes that are clearly deregulated during massive brain damage.
P Pr ro ot te eo om mi ic cs s a an nd d m me et ta ab bo ol lo om mi ic cs s i in n t th he e s se ea ar rc ch h f fo or r m ma ar rk ke er rs s o of f p pr ri io on n i in nf fe ec ct ti io on n
The only marker that is included in the World Health Organization (WHO) diagnostic criteria for sporadic CJD is 14-3-3 protein in CSF. This marker, alone or in combination with other neuron-specific, brain-derived proteins (neuronspecific enolase, Tau and phosphorylated Tau, and the astrocytic protein S100b), has been extensively evaluated and validated in all forms of human prion diseases (for comprehensive reports see [43] [44] [45] ). However, these tests only reach high levels of sensitivity and specificity if a patient is likely, on clinical grounds, to have sporadic CJD [44] ; it is thus important to maintain interest in and focus resources on finding novel and more specific markers for prion diseases.
In Table 1 , we report novel markers that have been identified in the CSF or plasma of patients with various forms of prion diseases. Data are not always comparable, due to the small number of prion patients and to the choice of controls, often taken from healthy individuals without including patients with different neurodegenerative disorders, rather than being due to the techniques used. These critical aspects were taken into serious consideration by Brechlin and co-workers [46] , who applied stringent criteria and appropriate neurological controls for the identification of five possible markers for sporadic CJD using two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Interestingly, three of these protein spots were subsequently identified as well-known markers for prion diseases (14-3-3, two spots, and neuronspecific enolase) and the fourth as lactate dehydrogenase, previously reported in sporadic CJD by the same group [47] .
The other interesting finding in these studies is that variant and sporadic CJD may present some different biochemical http://genomemedicine.com/content/1/6/63 Proteomic approaches have also been extensively used to investigate the pathogenesis of prion diseases, but the majority of these studies, even those conducted with experimental animal models, were performed in postmortem brain tissues, and it is therefore difficult to determine whether deregulation of identified proteins is a late result of neurodegeneration or specifically linked to prionspecific lesions. However, the finding that levels of proteins known to interact with Ca 2+ , or whose function is regulated by Ca 2+ , are significantly modified in the brains of affected animals [51] [52] [53] clearly deserves further investigation.
By analogy with other neurodegenerative disorders such as AD, the presence of oxidative stress has been investigated in different tissues, including CSF and blood from prionaffected individuals (Table 1) . These studies have shown the activation of several pro-and anti-oxidative mechanisms in prion disorders, but these pathways are shared by other neurological disorders and cannot be regarded as prionspecific biomarkers. Besides oxidative mechanisms, an atypical inflammatory response is activated in the central nervous system of prion-infected individuals, and consequently a number of (pro)inflammatory mediators are deregulated in the CSF of patients with prion diseases (Table 1 ) [40] . These mechanisms, however, are often common to other neurodegenerative disorders and may be of limited value as specific prion-disease markers.
Very few studies have been conducted for the identification of markers in human blood or urine [54] [55] [56] [57] . Among them, the heart-fatty acid-binding protein (H-FABP) has been found, by two different groups, to be increased in both CSF and plasma of individuals with sporadic and variant CJD [55, 56] . Blood manganese is another promising marker since its concentration is higher in the blood of individuals with sporadic CJD than in patients with other neurodegenerative disorders [57] .
S Sp pe ec ct tr ro os sc co op pi ic c a an nd d i im ma ag gi in ng g t te ec ch hn ni iq qu ue es s
Proton magnetic resonance spectroscopy ( 1 H-MRS) has been extensively applied for detecting metabolic alterations in the brain of prion-diseased patients [58, 59] . These studies, though conducted in a very limited number of patients, are very consistent and always confirm a reduction of N-acetylaspartate (NAA; a marker of neuronal loss), concomitant increase of myo-inositol (MI; an astrocyte marker), and a reduction of the NAA:creatine ratio. Interestingly, in a single asymptomatic carrier of the pathogenic mutation P102L (linked to GSS), Waldman and co-workers found an increase of MI with no variation of NAA [60] , suggesting that gliosis starts before massive neuronal loss, and that this compound may be a valid candidate as a preclinical marker of prion diseases.
The novel technology of atomic dielectric resonance spectroscopy (ADRS [61] ) has been demonstrated to discriminate between blood of CJD patients and that of neurological and healthy controls, as well as between sporadic and variant CJD patients, with 100% specificity and sensitivity. Though these data were blind-validated in only ten patients (four variant CJD, three sporadic CJD, and three non-neurological controls), they confirm data that have been previously reported for the sera of scrapieinfected rodents investigated by Fourier transform-infrared (FT-IR) spectroscopy [62] . It would therefore be interesting to extend the result obtained by Fagge and co-workers [61] to a larger number of patients and possibly to asymptomatic PRNP mutated carriers, to determine whether the ADRS signal might be useful to identify prion disease during the pre-or subclinical phase.
C Co on nc cl lu us si io on ns s
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